NR1H4 and Hepatic fibrosis: The farnesoid X nuclear receptor (FXR) ligand obeticholic acid showed promising results in reducing liver fibrosis, as shown in the FLINT [105] and REGENERATE [105] trials; however, there was an unfavorable effect on the lipid profile.